Related Experiment Videos
Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction
Sven Wassmann1, Stefan Hilgers, Ulrich Laufs
1Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
Arteriosclerosis, Thrombosis, and Vascular Biology
|July 16, 2002
Summary
Angiotensin II type 1 (AT1) receptor antagonist candesartan improved endothelial function in hypercholesterolemic patients by reducing oxidative stress and monocyte adhesion. This suggests a novel approach for preventing vascular dysfunction independent of blood pressure or lipid changes.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Endocrinology
Background:
- Hypercholesterolemia is linked to endothelial dysfunction, partly due to angiotensin II type 1 (AT1) receptor overexpression.
- Endothelial dysfunction is a critical factor in the development of cardiovascular diseases.
Purpose of the Study:
- To investigate the effect of AT1 receptor antagonism on endothelial function and inflammation in hypercholesterolemic patients.
- To compare candesartan with felodipine and placebo in treating hypercholesterolemia-induced endothelial dysfunction.
Main Methods:
- A 6-week randomized controlled trial involving 47 hypercholesterolemic patients.
- Treatment groups included candesartan (16 mg/d), felodipine (5 mg/d), and placebo.
- Endothelial function assessed via forearm blood flow (FBF) during reactive hyperemia; inflammation markers measured by ELISA.
Main Results:
- Candesartan significantly improved FBF during reactive hyperemia, unlike felodipine or placebo.
- Candesartan reduced serum concentrations of 8-isoprostane, monocyte chemoattractant protein-1, and soluble intercellular adhesion molecule-1.
- No significant changes in blood pressure, cholesterol, or other inflammatory markers (hs-CRP, TNF-α) were observed with any treatment.
Conclusions:
- AT1 receptor antagonism with candesartan improves endothelial function in hypercholesterolemia.
- Benefits include enhanced endothelium-dependent vasodilation, reduced oxidative stress, and decreased monocyte attraction/adhesion.
- AT1 receptor blockade offers a potential therapeutic strategy for vascular dysfunction in hypercholesterolemia, independent of lipid or blood pressure effects.